Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQV3IM)

Drug Name
SAR445088 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic inflammatory demyelinating polyneuropathy 8C01.3 Phase 2 [1]
Immune thrombocytopenia 3B64 Phase 2 [2]
Autoimmune haemolytic anaemia 3A20 Phase 1 [3]
Cold agglutinin disease 3A20.1 Phase 1 [4]
Cross-matching ID
TTD Drug ID
DMQV3IM

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C1s component (C1S) TT7LRQH C1S_HUMAN Inhibitor [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Complement C1s component (C1S) DTT C1S 12.194 10.051 9.335 8.798
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Chronic inflammatory demyelinating polyneuropathy
ICD Disease Classification 8C01.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C1s component (C1S) DTT C1S 5.50E-01 1.09 0.91
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04658472) A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04669600) A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP). U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04802057) An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04269551) A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease. U.S.National Institutes of Health.
5 First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.